尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶治疗晚期口腔癌的短期疗效观察

Clinical study on Nimotuzumab combined with Docetaxel-Cisplatin-Fluorouracil regimen in the treatment of advanced oral carcinoma

目的观察尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶(DCF)治疗晚期口腔癌的短期疗效及不良反应。方法 9例晚期口腔癌患者采用尼妥珠单抗联合DCF化学治疗方案:尼妥珠单抗200 mg,每周1次,连用6个周期;多西他赛75 mg.m-2,第1天,静脉滴注;顺铂75 mg.m-2,第1天,静脉滴注;氟尿嘧啶750 mg.m-2,第1～5天,每天持续静脉输注8 h。21天为l周期。结果对9例患者化学治疗后进行短期疗效评价示,有效率为88.89%,疾病控制率为100%。本研究化学治疗主要的不良反应有白细胞减少、恶心呕吐、脱发、电解质紊乱等。结论尼妥珠单抗联合DCF方案治疗晚期口腔癌短期内安全有效,可扩大样本量进行深入研究。

Objective To evaluate the efficacy and toxicity of Docetaxel-Cisplatin-Fluorouracil（DCF） regimen and Nimotuzumab on treating advanced oral carcinoma.Methods Nine patients with advanced oral carcinoma were collected and treated with the methods of DCF and Nimotuzumab in this study.All patients were given as follows： Nimotuzumab with 200 mg intravenous drip weekly for 6 weeks;Docetaxel and Cisplatin with 75 mg·m-2 each only used on the first day;Fluorouracil with 750 mg·m-2 infused continually for 8 hours from 1st to 5th day;the total cycle was 21 days.Results All nine patients were evaluated for objective response.The response rate was 88.89%.The disease control rate was 100%.The major side effects were as follows： Bone marrow suppression,nausea,vomiting,alopecia and so on.Conclusion The method of Nimotuzumab combining with DCF regimen was effective and safe on the treatment of advanced oral carcinoma.